Pradeep Mahal, MD
Gastroenterology · Union, NJNPI 1063551687
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,886 of the $4,515 with a category attached, or 86.1%. It is spread thinly across 40 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $988 and has fallen 82.5% since, to $173 in 2025.
Across 257 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$751
- Johnson & Johnson$671
- Pfizer$416
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$393
- AbbVie$386
- AVEO Pharmaceuticals, Inc.$325
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,88686%
- Education$62914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 48 | $751 |
| Johnson & Johnson | 21 | $671 |
| Pfizer | 28 | $416 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $393 |
| AbbVie | 28 | $386 |
| AVEO Pharmaceuticals, Inc. | 7 | $325 |
| Bristol Myers Squibb | 14 | $201 |
| Gilead | 11 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $92 |
| Intercept Pharmaceuticals, Inc. | 6 | $92 |
| Eisai Inc. | 6 | $88 |
| Bayer | 5 | $87 |
| Braintree Laboratories, Inc. | 5 | $84 |
| Tesaro, Inc. | 4 | $69 |
| Foundation Medicine, Inc. | 2 | $61 |
| Tempus AI, Inc | 2 | $60 |
| Redhill Biopharma Inc. | 4 | $55 |
| Rigel Pharmaceuticals, Inc. | 3 | $54 |
| Merck | 4 | $54 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Blueprint Medicines Corporation | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Advanced Accelerator Applications | 2 | $30 |
| Exact Sciences | 1 | $28 |
| Array Biopharma Inc | 2 | $27 |
| Novo Nordisk | 1 | $23 |
| Sobi, Inc | 1 | $19 |
| Incyte Corporation | 1 | $16 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Concordia Pharmaceuticals Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $14 |
| Madrigal Pharmaceuticals | 1 | $14 |
| GSK | 1 | $13 |
| Dova Pharmaceuticals | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Exelixis Inc. | 1 | $11 |
How this compares
$4,515 in reported general payments places this provider in the 65th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $206,841 |
| RinvoqUpadacitinib | 17 | $157,125 |
| Imatinib Mesylate | 15 | $77,906 |
| Famotidine | 694 | $19,474 |
| XareltoRivaroxaban | 11 | $17,996 |
| EliquisApixaban | 12 | $17,653 |
| JanuviaSitagliptin Phosphate | 14 | $16,592 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 55 | $8,825 |
| Sucralfate | 17 | $7,885 |
| Mesalamine | 12 | $7,207 |
| Mesalamine ErMesalamine | 12 | $5,840 |
| Ursodiol | 16 | $1,778 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 11 | $1,504 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,478 |
| Letrozole | 36 | $1,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $416 | $224,49525 claims |
| AbbVieRinvoq | $386 | $157,12517 claims |
| Johnson & JohnsonXarelto | $671 | $17,99611 claims |
| MerckJanuvia | $54 | $16,59214 claims |
| Braintree Laboratories, Inc.Sutab | $84 | $8,82555 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $393 | $1,50411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Union
- Vinod RustgiNew Brunswick$431K
- Zamir BrelviNewark$391K
- Adam ElfantMount Laurel$385K
- Devjit NayarHoboken$258K
- Lea ChenNew Brunswick$185K
- Alexander PerelmanWest Orange$160K
- Barry KaufmanEgg Harbor Township$157K
- Anish ShethPrinceton$151K
- Ramesh GuptaFair Lawn$143K
- Sanket PatelVoorhees$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.